» Articles » PMID: 15184887

Selective Inhibition of STAT3 Induces Apoptosis and G(1) Cell Cycle Arrest in ALK-positive Anaplastic Large Cell Lymphoma

Overview
Journal Oncogene
Date 2004 Jun 9
PMID 15184887
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusion gene product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL). It has been shown that NPM-ALK binds to and activates signal transducer and activator of transcription 3 (STAT3) in vitro, and that STAT3 is constitutively active in ALK(+) ALCL cell lines and tumors. In view of the oncogenic potential of STAT3, we further examined its biological significance in ALCL using two ALK(+) ALCL cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (AdSTAT3DN). Infection by AdSTAT3DN led to the expression of STAT3DN in both ALK(+) ALCL cell lines at a similar efficiency. Subcellular fractionation studies showed that a significant proportion of the expressed STAT3DN protein translocated to the nucleus, despite the fact that STAT3DN has a mutation at residue 705(tyrosine --> phenylalanine), a site that is believed to be crucial for STAT3 activation and nuclear translocation. Introduction of STAT3DN induced apoptosis and G(1) cell cycle arrest. Western blot studies showed that expression of STAT3DN resulted in caspase-3 cleavage, downregulation of Bcl-2, Bcl-xL, cyclin D3, survivin, Mcl-1, c-Myc and suppressor of cytokine signaling 3. These results support the concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression.

Citing Articles

ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.


Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.

Gupta V, Vashisht V, Vashisht A, Mondal A, Alptekin A, Singh H Genes (Basel). 2024; 15(4).

PMID: 38674331 PMC: 11049607. DOI: 10.3390/genes15040396.


Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma.

Shang C, Lai J, Haque M, Chen W, Wang P, Lai R Int J Mol Sci. 2023; 24(18).

PMID: 37762644 PMC: 10531997. DOI: 10.3390/ijms241814337.


De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.

Babin L, Darchen A, Robert E, Aid Z, Borry R, Soudais C Mol Cancer. 2022; 21(1):65.

PMID: 35246138 PMC: 8895835. DOI: 10.1186/s12943-022-01520-0.


Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia.

Chen Y, Hu J Ther Adv Hematol. 2020; 11:2040620719899818.

PMID: 32071709 PMC: 6997955. DOI: 10.1177/2040620719899818.